globulin follicular phase
Selected indexed studies
- Follicular lymphoma. (Nat Rev Dis Primers, 2019) [PMID:31831752]
- Bispecific antibodies in follicular lymphoma. (Haematologica, 2025) [PMID:39479864]
- Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study. (Haematologica, 2024) [PMID:37767550]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Bispecific antibodies in follicular lymphoma. (2025) pubmed
- Efficacy and safety of mosunetuzumab monotherapy for Japanese patients with relapsed/refractory follicular lymphoma: FLMOON-1. (2025) pubmed
- Differences in serum lipids, lipoproteins, sex hormone binding globulin and testosterone between the follicular and the luteal phase of the menstrual cycle. (1993) pubmed
- Follicular lymphoma. (2019) pubmed
- Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study. (2024) pubmed
- Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial. (2025) pubmed
- Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). (2019) pubmed
- Extracellular phase separation mediates storage and release of thyroglobulin in the thyroid follicular lumen. (2025) pubmed
- Subcutaneous epcoritamab monotherapy in Japanese patients with relapsed or refractory follicular lymphoma: primary results of the EPCORE NHL-3 trial. (2025) pubmed
- Obinutuzumab maintenance versus observation for patients with newly diagnosed high tumor burden follicular lymphoma who achieved complete metabolic response after obinutuzumab plus bendamustine induction therapy: a multicenter, randomized, phase III study (JCOG2008, MAIN study). (2025) pubmed